LP
MLYS icon

Longaeva Partners’s Mineralys Therapeutics MLYS Stock Holding History

Longaeva Partners’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.58M Buy
+281,104
New +$7.71M 0.17% 139

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Longaeva Partners's MLYS Position: Q2 2026 in Review

Longaeva Partners opened a new position in Mineralys Therapeutics (MLYS) in Q2 2026: 281,104 shares worth $7.58M. The stake represents 0.17% of the portfolio and ranks #139 among its holdings.

224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Longaeva Partners held 281,104 shares of Mineralys Therapeutics worth $7.58M as of Q2 2026.
  • Mineralys Therapeutics was a new Longaeva Partners position in Q2 2026.
  • Mineralys Therapeutics made up 0.17% of Longaeva Partners's portfolio in Q2 2026, its #139 holding.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Longaeva Partners's 13F filing for Q2 2026, filed 14 Aug 2026.